ERBB2 and breast carcinoma: To evaluate the antiproliferative effects of ipatasertib and taselisib as single agents or in combination with anti-microtubule chemotherapic agents, we used several human breast cancer cell models, including PI3Kα/Akt mutation negative and PI3Kα/Akt mutation positive cell lines, that have also different biologic profiles, according to the expression of HER2 and HR, as indicated in Table 1.